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Introduction: Ovarian dysfunction frequently occurs in female cancer patients after chemotherapy, but human
amniotic epithelial cells (hAECs) that can differentiate into cell types that arise from all three germ layers may offer
promise for restoration of such dysfunction. Previous studies confirmed that hAECs could differentiate into cells that
express germ cell-specific markers, but at this time hAECs have not been shown to restore ovarian function.
Methods: To model premature ovarian failure, hAECs infected with lenti-virus carrying green fluorescent protein
were injected into the tail vein of mice sterilized with cyclophosphamide and busulphan. hAECs migrated to the
mouse ovaries and overall ovarian function was measured using immunohistochemical techniques.
Results: Seven days to two months after hAECs transplantation, ovarian cells were morphologically restored in
sterilized mice. Hemotoxylin and eosin staining revealed that restored ovarian cells developed follicles at all stages.
No follicles were observed in control mice at the same time period. Immunostaining with anti-human antigen
antibodies and pre-transplantation labeling with green fluorescent protein (GFP) revealed that the grafted hAECs
survived and migrated to mouse ovary, differentiating into granulosa cells. Furthermore, the ovarian function
marker, anti-Müllerian hormone, was evident in treated mouse ovaries after hAEC transplantation.
Conclusions: Intravenously injected hAECs reached the ovaries of chemotherapy-treated mice and restored
folliculogenesis, data which suggest promise for hAECs for promoting reproductive health and improving the
quality of life for female cancer survivors.Introduction
Ovarian dysfunction or failure is common in premenopausal
women receiving chemotherapy and risk of such can be
predicted by the patient age and chemotherapeutic dosage.
Approximately 30% of women under the age of 35, 50%
of women aged 35 to 40 years, and 75 to 90% of women in
their 40s experience permanent cessation of menstrual
function after chemotherapy, leading to premature meno-
pause [1]. In vitro studies reveal that chemotherapy induces
apoptosis in pre-granulosa cells of primordial follicles,
reducing the likelihood of successful ovulation [2]. As* Correspondence: laidongmei@hotmail.com
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reproduction in any medium, provided the orsurvival rates for young cancer patients continue to
improve, protection against iatrogenic infertility caused
by chemotherapy will be of greater priority [3,4].
Recently, a gonadotropin-releasing hormone, (GnRH)
agonist has been used to minimize and prevent the
gonadotoxic effect of chemotherapy in humans, and data
show that patients treated with both a GnRH agonist and
chemotherapy resumed spontaneous ovulation and menses
or were able to conceive [5,6]. However, another stratagem
for this therapy may be treatment of ovarian failure caused
by chemotherapy.
Studies indicate that reproductive dysfunction can be
treated by bone marrow stem cells. In 2005, Johnson and
colleagues reported that bone marrow transplantation
restored oocyte production in wild-type mice sterilized by
chemotherapy, as well as in ataxia telangiectasia-mutatedtd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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making oocytes [7]. In 2007, the same group reported
that bone marrow transplantation generated immature
oocytes and rescued long-term fertility in a mouse model
of chemotherapy-induced premature ovarian failure [8].
However, Eggan and colleagues reported that the circulat-
ing bone marrow cells could not generate ovulated oocytes.
Instead, cells that travelled to the ovary through circulation
had characteristics of committed blood leukocytes [9].
Recently, Santiquet and co-workers reported that there
was no evidence that transplanted bone marrow cells
provided new fertilizable oocytes in a mouse model treated
with chemotherapeutic agents or with bovine embryonic
ovarian tissue grafts. However, transplanted bone marrow
cells did improve the fertility of severe combined im-
munodeficiency (SCID) mice previously treated with
chemotherapeutic agents [10].
Human amnion epithelial cells (hAECs) derived from
term placentas are anatomically and histologically special-
ized fetal epithelial cells and may maintain the pluripotent
properties of early epiblast cells. hAECs have been shown
to have the potential to differentiate in vitro into three
embryonic germ layers [11-13]. hAECs are discarded
post-partum and can be expanded extensively in culture, so
they may offer an alternate source useful for regenerative
medicine and cell therapy [14].
The formation of germ cells from the epiblast in the em-
bryo during gastrulation involves segregation of the primor-
dial germ cells (PGCs) from their somatic lineages and
migration of PGCs to the genital ridges. Because hAECs de-
velop from epiblasts prior to gastrulation, hAECs may have
the potential to differentiate into germ cells [15]. Recently,
Evron reported that hAECs cultured in media containing
serum substitute supplement (SSS) can differentiate into
oocyte-like cells and express germ cell specific markers [16].
Here, hAECs have been used to clarify the effects of cell
transplantation on female reproductive function using
a preclinical mouse model of chemotherapy-induced
premature ovarian failure. In this study we show - for the
first time - that hAECs can be grafted into the ovaries of
chemotherapy-treated mice and restore ovarian function.
Material and methods
Preparation and culture of hAECs
Human placentas were obtained at term pregnancy
during uncomplicated Caesarean sections with written
and informed consent from woman who tested negative
for HIV-I, and hepatitis B and C. The indication for
Caesarean section is breech presentation, repeat operation,
fetal distress and twins. The institutional ethics committee
approved the use of human amnions for this project. The
amniotic membranes were mechanically peeled from the
chorionic portion of the placenta placed in 250-ml flasks
containing RPMI 1640 medium, and cut with a razor toyield 0.5 to 1.0 cm2 segments. Placental segments were
digested with 0.25% trypsin/EDTA at 37°C for 45 minutes.
The resulting cell suspensions were seeded in a six-well
plate in RPMI 1640 medium supplemented with 10% FBS
(PAA Laboratories GmbH, Cölbe, Germany), streptomycin
(100 U/mL; Gibco, Grand Island, NY, USA), penicillin (100
U/Ml; Gibco, Grand Island, NY), and glutamine (0.3 mg/Ml;
Gibco), and incubated at 37°C 5% CO2 in humidified air.
Once hAECs reached 80 to 90% confluence, cells were ready
for experiments.
RNA extraction and real-time qPCR analysis
Total RNAs were isolated from samples using an RNeasy
Mini Kit (Qiagen, Chatsworth, CA, USA). Five hundred
nanograms of total RNA from each sample were used in
reverse transcription (RT) using an iScript cDNA synthesis
kit (Bio-Rad, Hercules, CA, USA). Real-time RT-qPCR was
performed on cDNA using IQ SYBR Green (Bio-Rad) on
the Mastercycler® ep realplex (Hamburg, Germany). All re-
actions were performed in a 25-μl volume. Primer se-
quences are listed in Additional file 1: Table S1. Reaction
conditions for STELLA, STRA8 and DAZL were: 94°C for 2
minutes, then 94°C for 30 sec, 60°C for 30 sec, 72°C for 45
sec, 28 cycles, then 72°C for 10 minutes; conditions for
OCT4, CD117, HLA-DR, BLIMP1, VASA, SCP1,SCP3 and
18 s RNA were: 94°C for 2 minutes, then 94°C for 30 sec,
53°C for 30 sec, 72°C for 45 sec, 28 cycles, then 72°C for
10 minutes; conditions for NANOG and c-MOS were: 94°C
for 2 minutes, then 94°C for 30 sec, 60°C for 30 sec, 72°C
for 45 sec, 28 cycles, then 72°C for 10 minutes.
Animals
C57BL/6 wild-type female mice, six-weeks-old (18.15 ±
0.16 g by weight), were sterilized by intraperitoneal injec-
tion of busulfan (Sigma-Aldrich, 30 mg/kg; resuspended
in dimethyl sulfoxide (DMSO)) and cyclophosphamide
(Sigma-Aldirich, 120 mg/kg; resuspended in DMSO) were
used as recipients [17]. Normal control mice were injected
with DMSO only. All procedures for animals were ap-
proved by the Institutional Animal Care and Use Commit-
tee of Shanghai, and were performed in accordance with
the National Research Council Guide for Care and Use of
Laboratory Animals.
Transfection and transplantation of hAECs
The hAECs grown to a density of 80 to 90% were used,
and lenti-virus enhanced with green fluorescent protein
(EGFP, a gift from Tianjin Liu) [18] was added to cultured
cells and incubated for 24 h. Titration of concentrated
supernatants was performed by serial dilutions of vector
stocks on 1 × 105 Hela cells followed by fluorescence-
activated cytometric analysis according to the formula:
1 × 105 Hela cells × % EGFP positive cells × 1,000/μl
virus. Titers of lenti-viral vectors were 1× 108 - 1 × 109
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examined by fluorescence microscopy. The overall cell
transfection rate was determined to be greater than 95%.
After lenti-viral infection for two days, hAECs were washed
three times and trypsinized (0.25% trypsin), neutralized in
10% FBS, washed with phosphate-buffered saline (PBS)
and resuspended in the culture medium.
To transplant hAECs into mouse ovaries, mice were
anesthetized with an intraperitoneal injection of pentobar-
bital sodium (45 mg/kg ). Approximately 6 μl of a single-
cell suspension (2 × 106 cells), or 6 μl of culture medium
for the untreated control group, were injected into mouse
tail veins one week after chemotherapy.
Immunohistochemical analysis
Ovaries from treated and control animals were fixed with
4% paraformaldehyde (4°C, overnight), dehydrated through
a graded ethanol series, vitrified in xylene, and embedded in
paraffin. Sections (6-μm thick) were fixed for 5 minutes in
neutral buffered formalin, after which endogenous peroxid-
ase activity was quenched by incubating the sections in 0.3%
hydrogen peroxide in methanol for 30 minutes. Sections
were treated with mouse anti-human anti-Müllerian hor-
mone (AMH, 1:30; AbD Serotec, Oxford, United Kingdom),
anti-human specific nuclear antigen (monoclonal antibody,
1:300; EMD Millipore, Darmstadt, Germany), or mouse
anti-human follicular stimulating hormone receptor (FSHR,
1:100; Abcam, Cambridge, England) for antibody detection.
Peroxidase reaction kits (Vector Laboratories, Burlingame,
CA, USA) were used according to the manufacturer’s instruc-
tions. Peroxidase substrate was developed by using a DAB
(3,39-diaminobenzidine) substrate kit (Vector Laboratories).
Slides were counterstained with hematoxylin QS (Vector
Laboratories) and were either mounted with low viscosity
aqueous mounting medium (Scytek Laboratories, Logan,
UT, USA) or dehydrated and mounted with VectaMount
Permanent Mounting Medium (Vector Laboratories).
Immunofluorescence staining
hAECs were fixed with 4% paraformaldehyde for 15 to 20
minutes at room temperature, and then washed twice (10
minutes each) with 1 × PBS. Cells were permeabilized with
0.1% Triton X-100 for 10 minutes at room temperature, and
then washed twice with 1 × PBS. Then cells were blocked
with blocking solution for 30 minutes and incubated with
anti-OCT4 (rabbit anti-human 1:200, Santa Cruz Biotechnol-
ogy, Santa Cruz, CA, USA), anti-VASA antibody (goat
antihuman 1:200, Santa Cruz), anti-DAZL (goat anti human
1:500, Santa Cruz), anti-STELLA (goat anti Human 1:200,
Santa Cruz), anti-NANOG (rabbit anti human 1:200,
Millipore), anti-CD117 (Rabbit antihuman 1:800, eBioscience,
CA, USA) antibody for 1 h at room temperature. Ovaries
from treated and control animals were fixed with an optimal
cutting temperature (OCT) compound (Sakura Finetek,Seattle, USA) and 5-μm thick fresh sections were made. Slides
were washed twice with PBS and blocked with blocking
solution for 30 minutes at room temperature and then
incubated overnight at 4°C with rabbit polyclonal anti-GFP
(dilution 1:200; Chemicon, Massachusetts, USA) or mouse
anti-human nuclear monoclonal antibody (dilution 1:50;
Millipore, Massachusetts, USA). Then cells or sections were
washed three times with 1 × PBS, and probed with
FITC-labeled IgG (1:200, Santa Cruz, CA, USA) or Rodamine
(TRITC)-labeled IgG (1:100, Invitrogen, CA, USA).
Fluorescence images were obtained with a Leica DMI3000
microscope (Heidelberg, Germany).
Statistics
Means for relative gene expression were compared by
ANOVA using Microsoft Excel software.
Results
hAECs express stem cell markers, but not germ cell markers
To examine germ cell-specific genes in hAECs, six inde-
pendent hAECs were cultured for one week. A portion of
the attached cells were collected and assayed. Real-time
PCR was used to assess markers expressed by hAECs (See
Additional file 1: Table S2). As expected from previous
reports [11,12], we observed consistent expression of the
human OCT4 and NANOG gene in all six samples. The
cells also expressed markers of the surface antigen C-KIT
(CD117); however, major histocompatibility (MHC) Class II
(HLA-DR) expression was modestly expressed (Figure 1A).
Next we measured expression of germ-cell-specific genes in
hAECs, including BLIMP1 (B-lymphocyte-induced matur-
ation protein 1), STELLA (developmental pluripotency-
associated protein 3, stella-related protein), DAZL (deleted
in azo-ospermia-like), VASA (probable ATP-dependent
RNA helicase DDX4, vasa homolog), STRA8 (stimulated by
retinoic acid gene 8), c-MOS (oocyte maturation factor
mos), and SCP1 and SCP3 (syntaptonemal Complex Protein
1 and 3). Comparatively, mRNA expression of pre-meiotic
germ genes, including BLIMP1 and STRA8, were low, and
STELLA, DAZL,VASA and the meiotic genes, such as SCP1
and SCP3, were lower still (Figure 1A). Consistent with
the transcriptional profiles, OCT4, NANOG and CD117,
expressions were detectable in hAECs at the protein level
using immunofluoresence. However, DAZL, STELLA and
VASA protein were not detectable in these cells (Figure 1B).
Consistent with a previous study [16], these data suggest
that germ cell markers are not expressed in hAECs.
hAECs rescues oocyte production in
chemically-damaged ovaries
To assess whether hAECs could migrate to ovaries and
restore ovarian function, wild-type female mice were
sterilized by pre-treatment with cyclophosphamide and
busulfan to destroy the existing pre- and post-meiotic
Figure 1 Human amniotic epithelial cells (hAECs) did not express germ-cell-specific genes. (A) Quantitative PCR was used to analyze
germ-cell-specific expression in hAECs. CT values were expressed as a percentage of 18S RNA (18S = 100%) and used to calculate mean
normalized expression relative to 18S. Results are shown as mean and standard deviation of three experiments. (B) Immunofluorescence analysis
of germ-cell-specific genes in hAECs. Note that hAECs expressed OCT4 (red), NANOG (green) and CD117 (green), but did not express DAZL,
STELLA or VASA. DAPI staining for nuclei. Scale bars = 50 μm.
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recipients”. The hAECs grown to 85% density were infected
with lenti-virus carrying GFP (Figure 2A, B). After infection
and culture for an additional week, 2 × 106 hAECs were
transplanted by tail vein injection into recipient females
seven days after chemotherapy (n = 20). The untreated
control group received 6 μl of culture medium (n = 15).
No transplant-related deaths occurred.
As shown in Figure 2, seven days to two months after
transplantation, mouse ovaries were collected, counted
and assayed for the presence of oocytes as determined by
their morphological appearance and expression of GFP.
Histological evaluations seven days to two months after
chemotherapy revealed that the chemotherapy regimen
essentially destroyed total immature (primordial, primary,
secondary) follicles in recipient ovaries which did not
receive hAEC transplantation (Figure 2M). Untreated
control ovaries contained little more than stromal and
interstitial cells with an increasing atretic follicle and
they lack GFP expression (Figure 2E-I, M, Figure 3S-U).
However, GFP expression was observed and presented as
distributed “found as dots” in these ovaries (Figure 3A-C).
Ovaries of mice receiving hAECs transplantation at 14
days and 21 days possessed primary and developing
follicles (Figure 2J, K, M), in which GFP expression
and GFP-positive follicles were found (Figure 3D-I). By
comparison, ovaries of mice receiving hAECs two months
after chemotherapy possessed immature and mature
oocyte-containing follicles (Figure 2L), including GFP-positive follicles (Figure 3J-R), similar to ovaries that had
not been sterilized (Figure 2C, D, controls were injected
with DMSO only, n = 10).
Interestingly, GFP-labeled cells were irregularly distrib-
uted seven days after hAEC transplantation (Figure 3A-C),
and these were subsequently detected in ovarian tissue near
the follicles 14 days (Figure 3D-F), 21 days (Figure 3G-I)
and 28 days (Figure 3J-L) after hAECs transplantation,
finally proximally situated near the follicles two months
after hAECs transplantation (Figure 3M-R).
These experiments demonstrated that follicles can be
regenerated in sterile females by hAECs transplantation.
hAECs-derived cells infiltrate into the chemical-damaged
murine ovarian tissue
To confirm whether GFP-positive cells in recipient ovaries
were indeed derived from grafted hAECs, we performed
double-staining with GFP and human specific nuclear
antigen in recipient ovarian sections 28 days or 2 months
after hAECs transplantation. GFP positive staining co-local-
ized with human anti-nuclear staining in ovarian stroma
(Figure 4A-F) and in antral follicles (Figure 4G-L).
Immunohistochemical analysis with human nuclear
antigen was used to measure survival and differentiation
of grafted hAECs. Human specific nuclei were expressed
in some follicles of recipient ovaries two months after
hAECs transplantation (Figure 5C, D), whereas human-
specific nuclear expression was negative for ovaries that
did not receive hAECs transplantation (Figure 5A).
Figure 2 Transplantation of GFP-transfected hAECs into sterilized recipient mice and the follicle activation induced by hAECs
transplantation. (A) hAECs cells grown to 85% density. (B) GFP-transfected hAECs. Representative H&E micrographs of ovary sections from: non-
sterilized normal control mice (C, D); sterilized non-transplanted mice after a 7-day recovery period (E), a 14-day recovery period (F), a 21-day
recovery period (G) and a 2-month recovery period (H) showing stroma, and atretic primordial or primary follicles; sterilized recipient mice 7 days
(I), 14 days (J), 21 days (K) and 2 months (L) after transplantation of hAECs. No obvious follicles were observed in recipients seven days after
hAEC transplantation (I); however, the hollow structure destroyed by chemotherapy was reduced and obviously compared with (E). Primordial
follicles are visible in J, primary follicles were visible in K and large antral follicles are shown in L. Arrows indicated follicles at various stages of
maturational development. Scale bars = 100 μm. (M). Differential follicle counts of primordial, primary, secondary and atretic follicles in ovaries of
each groups. NC, Normal control; UC, Untreated control; hAECs, hAECs transplantation group. GFP, Green fluorescent protein; hAECs, Human
amniotic epithelial cells.
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Figure 3 Macroscopic appearance of recipient ovaries seven days to two months after transplantation with GFP-transfected hAECs.
(A-F) GFP staining dots shown in recipient ovaries 7 to 14 days after transplantation with GFP-transfected hAECs, whereas no GFP signal was
observed in follicles. Follicles containing GFP-positive (green) cells were shown in recipient ovaries 21 days (G-I), 28 days (J-L) and 2 months
(M-R) after transplantation with GFP-transfected hAECs. (S-U) Oocytes in recipients without hAECs transplantation had no GFP signal after a
two-month recovery period. Arrows indicate the GFP distribution pattern in ovaries. Blue, DAPI immunofluorescence. Scale bars, 200 μm (S-U),
100 μm (A-R). GFP, Green fluorescent protein; hAECs, Human amniotic epithelial cells.
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granulosa cells near the ovum, whereas the other granulosa
cells were not stained (Figure 5C, D). Next, human
follicle-stimulating hormone receptor (FSHR) was used
to characterize the grafted cells. FSHR, a glycoprotein
hormone receptor, can serve as a granulosa cell marker
and is required for normal ovarian development and
follicle maturation in females [21]. In addition, human
FSHR can also be used as a human cell transplantation
tracking marker. Using an immunochemical assay, human
FSHR staining patterns were observed to be similar to
human-specific nuclear antigen and human FSHR was only
detected in cells proximal to the eggs in ovarian tissue two
months after hAECs transplantation (Figure 5G, H).
These results strongly suggest that a portion of hAECs-
derived cells were grafted to the chemotherapeutically mur-
ine ovarian tissue and participated in follicle production.
Grafted hAECs partially restore ovarian function in
chemotherapy-treated mice
AMH is a member of the transforming growth factor β
family of growth and differentiation factors. In humans,
it is encoded by the AMH gene which is expressed byovarian granulosa cells in reproductive ages. AMH controls
the formation of primary follicles by inhibiting excessive
follicular recruitment by FSH. AMH is strongly correlated
to the follicle pool size. It, therefore, has a role in
folliculogenesis and can be used as a marker of ovarian
aging, responsiveness and pathophysiology [22]. As shown
in Figure 6A, AMH expression was strong in granulosa
cells of preantral and small antral follicles in normal ovar-
ies, but AMH was not expressed in ovaries sterilized with
chemotherapy (Figure 6B). AMH was not detected in re-
cipient ovaries seven days after hAECs transplantation
(Figure 6C); however, AMH expression appeared in
primary follicles of recipient ovaries 14 days after hAECs
transplantation (Figure 6D), and strong expression of
AMH was observed in recipient ovaries 21 days and 2
months after hAECs transplantation (Figure 6E, F).
These results demonstrate that ovarian function can
be partially restored in sterile recipient females by trans-
plantation of hAECs.
Discussion
Infertility is functionally defined as the inability of a person
to contribute to conception. Cancer treatment, such as
Figure 4 Double-staining with GFP and human nuclear antigen to observe GFP-positive cells after hAECs transplantation.
(A-F) Ovarian sections stained with GFP and anti-human nuclear antibody reveal grafted hAECs 28 days after hAEC transplantation. (G-L) GFP
staining co-localized with human nuclear antigen in antral follicles of recipient ovaries two months after hAEC transplantation. Arrows indicate a
double-staining pattern in ovaries. Scale bars, 200 μm (G-L), 100 μm (A-F). GFP, Green fluorescent protein; hAECs, human amniotic epithelial cells.
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decrease the number of primordial follicles, affect hormo-
nal balance, or interfere with the functioning of the ovaries,
fallopian tubes, uterus or cervix. Anatomic or vascularchanges to the uterus, cervix or vagina from surgery or
radiation may also prevent natural conception and
successful pregnancy, requiring assisted reproductive
technology or use of a gestational carrier. Unfortunately,
Figure 5 Grafted cells detected by immunochemistry against human antigens. (A) Human specific nuclear antigen expression was negative
in recipient ovaries without hAECs transplantation. (B) Human nuclear antigen was not detected in some recipient ovaries two months after
hAEC transplantation. (C, D) Human nuclear antigen was expressed in antral follicles in recipient ovaries two months after hAEC transplantation.
(E) Human FSHR was not detected in recipient ovaries without hAEC transplantation. (F) Human FSHR was not detected in some recipient
ovaries two months after hAEC transplantation. (G, H) Human FSHR were detected in recipient ovaries two months after hAEC transplantation.
Arrows indicate human antigen expression in granulosa cells surrounding the ovum, whereas other granulosa cells were negative controls. Scale
bars = 100 μm. hAECs, human amniotic epithelial cells.
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people with cancer, and the quality of life of cancer survi-
vors after chemotherapeutic or radiologic treatments is an
increasing concern, specifically with respect to restoring
gonadal function and reviving fertility [23]. Stem cells areFigure 6 AMH expression in recipient mouse ovaries. (A) AMH was exp
follicles in normal ovaries. (B) AMH expression disappeared in stromal and
months after chemotherapy. (C) AMH expression was negative in recipient
expressions were detected in recipient ovaries after hAEC transplantation fo
in recipient ovaries two months after hAEC transplantation; data are consis
Anti-Müllerian hormone; hAEC, human amniotic epithelial cell.unique cells with the potential for not only self-renewal
but also the ability to differentiate into specialized progeny.
Evidence suggests that transplantation of stem cells from
bone marrow can restore ovarian function that has been
destroyed by gonadotoxic insults [8,10]. Recently, Ghadamiressed in all granulosa cells of primary, preantral and small antral
atretic follicles in recipients ovaries without hAECs transplantation two
ovaries seven days after hAEC transplantation. However, AMH
r 14 days (D) and 21 days (E). (F) AMH expression patterns are strong
tent with that from control normal ovaries. Scale bars = 100 μm. AMH,
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plantation could restore follicular maturation and steroid
hormone production in a follitropin receptor knockout
(FORKO) mouse model used to study primary ovarian fail-
ure [24]. Irrespective of current stem cell controversies,
general agreement exists regarding the utility of stem cell
therapy, such as bone marrow stem cells, for improving
ovarian function.
Adult bone marrow (BM) is the most common source
of clinically used mesenchymal stem cells (MSCs). How-
ever, adult BM has limitations. First, the frequency of MSCs
in adult BM is low. Second, harvesting BM from a patient
is invasive. Therefore, alternative sources of MSCs are
needed for future clinical applications. Compared with BM
or other adult stem cells, hAECs have enormous potential
for serving as a stem cell source for basic science and
regenerative medicine. hAECs can differentiate into cells
from all three embryonic tissue types, such as ectoderm
cells (neural cells), mesodermal cells (cardiomyocytes) and
endodermal cells (hepatocytes and pancreatic cells) [11-13].
Moreover, hAECs can be isolated from term placentas
without the sacrifice of human embryos and the cells can
be readily cryopreserved for cell banking. Therefore, hAECs
represent a powerful tool for cellular therapy for different
human diseases, such as neurodegenerative diseases and
nervous system injuries [25], hepatic fibrosis [26] and
myocardial infarction (cardiac and smooth muscles) [27].
However, at this time whether hAECs can restore ovarian
function is unclear.
To address this, we analyzed hAECs for expression of
germ cell markers. As expected from a previous report
[11,12], we observed consistent expression of OCT4,
NANOG and CD117 expression in hAECs. Then, we
measured expression of additional germ-cell-specific
genes of hAECs. In hAECs, we did not observe expression
of genes known to be restricted in the expression of germ
cell differentiation. Recent studies showed that hAECs can
express germ-cell-specific markers [16], suggesting that
hAECs can restore ovarian function after transplantation
into chemotherapeutically damaged ovaries.
Using a preclinical mouse model of chemotherapy-
induced ovarian failure, hAECs were transfected with
GFP lenti-virus and were transplanted via tail vein
injection one week after chemotherapy-induced sterility.
Timing of transplantation was guided by the report of Lee
and colleagues who suggested that the maximum benefit
of stem cell transplantation was achieved when transplant-
ation occurred one week after chemotherapy [8]. One week
after transplantation, hAECs-derived GFP-positive cells
were observed in ovaries, and primordial follicles could be
found in recipient ovaries two weeks after hAECs trans-
plantation. Various stages of developing follicles, including
GFP-stained follicles could be observed three weeks to two
months after hAECs transplantation. Double-staining withGFP and human specific nuclear antigen demonstrated
that GFP-positive cells in recipient ovaries were derived
from grafted hAECs. Importantly, human specific nuclear
antigen expression was observed in granulosa cells sur-
rounding the ovum, but not egg cells. Furthermore, human
FSHR expression patterns in recipient ovarian follicles
were localized to all ovarian granulosa cells of the Graafian
follicles [20]. Human FSHR expression in sterilized ovaries
indicated that a portion of the grafted hAECs differentiated
into granulosa cells, but not germ cells.
Further, the ovarian function of infertile mice was
improved after hAECs transplantation. Because AMH
is correlated with the size of the follicle pool, it can be
used as a marker of ovarian aging, responsiveness and
pathophysiology [22,28], and serum AMH has been
used as a clinical marker of ovarian function. AMH has
been reported to be a promising marker for premature
ovarian failure in both healthy women and those with
Turner syndrome [29]. AMH measurements at cancer
diagnosis also predict long-term ovarian function after
chemotherapy; so this marker may better predict chemo-
therapy-related risk to future fertility [30]. Our results
showed that AMH was strongly expressed in the ovary of
infertile mice three weeks to two months after transplant-
ation. However, AMH expression was not detected in
recipient ovaries until two weeks after transplantation,
suggesting that after transplantation at least two weeks
must elapse before restoration of ovarian function is
obtained in infertile mice.
The mechanisms of stem cell transplantation for the
treatment of different disorders remain unclear at this
time, and controversies exist about their use. Evidence
suggests that the microenvironment of injury could affect
the migration, adherence and differentiation of transplanted
stem cells [31-33]. Transplanted stem cells might trans-
differentiate to tissue-specific cells, or fuse with the existing
native cells, to improve the organ function by contributing
their own genetic and cellular materials [33,34]. The de-
velopment of ovarian follicles requires complex cell-cell
interactions, as well as communication between somatic
and germ cells. In the developing oocyte, granulosa cells
surround the oocyte, support its growth, and provide
hormonal supplementation, so normal granulosa cell
communication and development is critical for oocyte
growth [35]. This is important because a previous study
suggested that cyclophosphamide (CTX) metabolites might
decrease granulosa cell function and induce ovarian
toxicity during CTX therapy [36].
In this study, we found that GFP-labeled cells initially
entered into ovarian stroma, and then distributed prox-
imal to the follicles, and finally surrounded the oocytes
(Figures 3 and 4). Further, human FSHR could be detected
in cells surrounding the oocytes in ovarian tissue two
months after transplantation. Thus, hAECs may integrate
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http://stemcellres.com/content/4/5/124into the ovaries of infertile mice, and some hAECs may
transdifferentiate to granulosa cells and direct follicle de-
velopment. Recently, evidence was reported that ovaries
of reproductive-age women, similar to adult mice, possess
rare germ line stem cells [17,37], which might explain the
observation that ovarian function after chemotherapy can
be restored spontaneously in some cases [8]. However, our
results revealed that all of the sterilized mouse ovaries
produced follicles after hAEC transplantation, whereas
only a few of control ovaries responded in this manner.
Thus, we believe that hAECs function primarily by reacti-
vating host gem line stem cells. Additional experiments
are necessary to elucidate the exact mechanisms by which
stem cell transplantation restores ovarian function.
Previous studies indicate that amniotic epithelial cells had
no karyotypic abnormalities or transformation potential
in vitro and no tumorigenic effects in vivo [14]. Evidence
also suggested that the amniotic epithelial cells had
immunosuppressive properties [38,39]. Here C57BL/6
mice (not SCID mice) were used to model ovarian failure.
Mice receive no immunosuppressive agents before hAEC
transplantation, and no transplant-related deaths were ob-
served after hAEC transplantation. However, the immuno-
logical rejection of hAECs needs to be further elucidated
before clinical application.Conclusion
In summary, hAECs derived from term placentas after
live birth may have the intrinsic ability to restore folli-
culogenesis, and hAEC transplantation may be a testable
clinical strategy for preserving or resurrecting ovarian
function in female cancer patients after chemotherapy.
Our findings have implications for the future use of stem
cells for the improvement of the quality of life in cancer
survivors.Additional file
Additional file 1: Table S1. Real-time PCR primer sequences. Table S2.
Real-time PCR in human amniotic epithelial cells (hAECs). Mean
normalized expression of genes in hAECs were calculated by 2(−ΔCt).
Results are shown as mean and standard deviation of three experiments.
18 s RNA was used as internal control.
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